Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios--
--Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava in
--Leverage both in-house discovery and strategic business development to establish industry leadership and global footprint--
"Everest had impressive growth over the past five years, evolving from its successful in-licensing model to developing strong capabilities in both self-discovery and business development, both of which we will continue to leverage as we transition into a fully integrated biopharma company and establish ourselves as an
The potential approval and launch of Nefecon, the Company's lead renal portfolio product candidate, is expected in
In parallel, the Company aims to initiate clinical trials and file an Emergency Use Authorization application in 2023 in
In addition to the Company's focus on renal diseases and mRNA platform, it is also pursuing several product candidates in the pipeline with best-in-class potential, including Xerava which is also expected to receive NDA approval in 2023, and etrasimod for the treatment of ulcerative colitis.
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
View original content:https://www.prnewswire.com/news-releases/everest-medicines-announces-new-strategic-plans-reinforcing-transformation-into-a-fully-integrated-biopharmaceutical-company-301712171.html